GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hangzhou Minsheng Healthcare Co Ltd (SZSE:301507) » Definitions » Debt-to-EBITDA

Hangzhou Minsheng Healthcare Co (SZSE:301507) Debt-to-EBITDA : 0.01 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Hangzhou Minsheng Healthcare Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hangzhou Minsheng Healthcare Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1.0 Mil. Hangzhou Minsheng Healthcare Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥0.8 Mil. Hangzhou Minsheng Healthcare Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥273.5 Mil. Hangzhou Minsheng Healthcare Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Hangzhou Minsheng Healthcare Co's Debt-to-EBITDA or its related term are showing as below:

SZSE:301507' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02   Med: 0.18   Max: 0.4
Current: 0.02

During the past 6 years, the highest Debt-to-EBITDA Ratio of Hangzhou Minsheng Healthcare Co was 0.40. The lowest was 0.02. And the median was 0.18.

SZSE:301507's Debt-to-EBITDA is ranked better than
96.8% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs SZSE:301507: 0.02

Hangzhou Minsheng Healthcare Co Debt-to-EBITDA Historical Data

The historical data trend for Hangzhou Minsheng Healthcare Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Minsheng Healthcare Co Debt-to-EBITDA Chart

Hangzhou Minsheng Healthcare Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 0.33 0.37 0.03 0.03 0.02

Hangzhou Minsheng Healthcare Co Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.04 0.06 0.12 0.01

Competitive Comparison of Hangzhou Minsheng Healthcare Co's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Hangzhou Minsheng Healthcare Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Minsheng Healthcare Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hangzhou Minsheng Healthcare Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hangzhou Minsheng Healthcare Co's Debt-to-EBITDA falls into.



Hangzhou Minsheng Healthcare Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hangzhou Minsheng Healthcare Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.045 + 1.085) / 124.607
=0.02

Hangzhou Minsheng Healthcare Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.045 + 0.843) / 273.472
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Hangzhou Minsheng Healthcare Co  (SZSE:301507) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Hangzhou Minsheng Healthcare Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hangzhou Minsheng Healthcare Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Minsheng Healthcare Co (SZSE:301507) Business Description

Traded in Other Exchanges
N/A
Address
No. 101, Xintian Road, Donghu Street, Linping, Zhejiang, Hangzhou, CHN, 311100
Hangzhou Minsheng Healthcare Co Ltd focuses on the field of vitamin and mineral supplements and is a high-tech enterprise integrating research and development, production and sales of vitamin and mineral over-the-counter drugs and health food. The company's current main product is 21 Golden Vita multi-dimensional element tablets (21).

Hangzhou Minsheng Healthcare Co (SZSE:301507) Headlines

No Headlines